<DOC>
	<DOC>NCT01003899</DOC>
	<brief_summary>To explore the efficacy of BIBW 2992 defined by the objective response rate (Complete Response, Partial Response) as determined by Response Evaluation Criteria in Solid Tumours[RECIST] 1.1 in the patients with advanced (stage IIIB or IV) adenocarcinoma of the lung harbouring wild-type EGFR.</brief_summary>
	<brief_title>A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Inclusion criteria: 1. Pathologically confirmed stage IIIB/IV adenocarcinoma in nonsmall cell lung cancer[NSCLC] 2. Progressive disease following a secondline cytotoxic chemotherapy including at least one platinumcontaining regimen 3. A known wildtype EGFR status 4. Patients 18 years of age or older Exclusion criteria: 1. More than two prior cytotoxic chemotherapy treatment regimens for relapsed or metastatic disease 2. Prior treatment with EGFR targeting small molecules or antibodies 3. Radiotherapy or surgery within 4 weeks prior to study entry 4. Active brain metastasis 5. Known preexisting interstitial lung disease 6. History or presence of clinically relevant cardiovascular abnormalities 7. Cardiac left ventricular function with resting ejection fraction of less than 50% 8. Absolute neutrophil count[ANC] &lt; 1,500/mm3 9. Platelet count &lt;100,000/mm3 10. Creatinine clearance&lt;60ml/min or serum creatinine &gt;1.5 times upper limit of normal 11. Women of childbearing potential, or men who are able to father a child, unwilling to use a medically acceptable method of contraception during the trial 12. Pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>